Stockwinners Market Radar for November 08, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:14 EST Lemonade to acquire Metromile in all-stock transaction valued at roughly $500M - Lemonade (LMND) and Metromile (MILE) have entered into a definitive agreement pursuant to which Lemonade will acquire Metromile in an all-stock transaction that implies a fully diluted equity value of approximately $500 million, or just over $200 million net of cash. Under the terms of the transaction, Metromile shareholders will receive Lemonade common shares at a ratio of 19:1. "We launched Lemonade Car last week, and we think you'll love how it looks and handles. Pop the hood and you'll see that it's powered by telematics and architected to learn from the data it generates, with precision pricing as its ultimate destination," said Daniel Schreiber, Lemonade CEO and cofounder. "That's where Metromile comes in. They have been down this road billions of times, and their proprietary data and machine learning algorithms can vault us over the most time and cost intensive parts of the journey. In a vast and competitive market like auto insurance, today's deal is a huge unlock of value for our customers and shareholders." The transaction is expected to close during Q2 2022, once all regulatory approvals have been secured. The transaction requires the approval of Metromile stockholders, and is subject to other customary closing conditions.

16:12 EST Virgin Galactic says start of commercial service on track for Q4 of 2022

16:10 EST RH chief operating, services, and values officer DeMonty Price to retire - RH announced the following leadership changes in the attached letter from the Company's Chairman & CEO Gary Friedman. "DeMonty Price, President, Chief Operating, Service and Values Officer, has informed the Company of his plans to retire from RH to spend time with his family, effective January 29, 2022, the end of the fiscal year... Stefan Duban, Senior Vice President & Chief Gallery Officer is being promoted to Chief Gallery & Customer Officer of RH, and will be responsible for the Global Operations of the Company's Galleries, Interior Design, Hospitality, Trade, Contract, Outlet and Gallery Optimization Teams. Stefan is in his 22nd year at RH, and began his career as a part time sales associate in our Thousand Oaks, CA Gallery. He has held the positions of Gallery Leader, Vice President of Home Delivery, Vice President and Regional Field Leader, and most recently, Chief Gallery Officer of RH. Fernando Garcia, who joined RH as President of Home Delivery in the Spring of 2019 and assumed responsibility for the Company's Distribution Centers, Logistics and Transportation in November of that year, is being promoted to Chief Supply Chain Officer and President of Home Delivery. Fernando will continue to lead the Global Operations of the Company's Distribution Centers, Home Delivery, and Transportation Teams. Prior to RH, Fernando was President & CEO of FGO Logistics, a home delivery business he founded in 2006, growing the company to an organization with over 550 trucks delivering to homes across 31 states, and serving companies such as RH, Home Depot, Best Buy, Crate & Barrel, Ashley and other national firms. Fernando sold FGO in 2019 in order to join RH. Sandy Pilon, Chief People Officer will continue in her current role while reassuming responsibility for the Global Operations of the Company's Customer Delight Centers and will be responsible for leading our Company's values. Sandy's new title will be Chief People & Values Officer of RH. Sandy is a 13-year member of Team RH, beginning her career as a District Field Leader in 2008. She has held the positions of District Field Leader, Regional Field Leader, Vice President and Field Leader of the Western States, Senior Vice President of Customer Delight, and most recently Chief People Officer."

16:08 EST Tencent Music reports Q3 online music paying users reached 71.2M, up 37.7% y/y - Online music paying users reached 71.2M, increasing by 37.7% year-over-year. On a sequential basis, the number of online music paying users grew by 5M. Paying ratio was 11.2%, up from 8.0% in the third quarter of 2020 and 10.6% in the second quarter of 2021, respectively.

16:04 EST Medavail to open initial three SpotRx locations with InnovaCare in Florida in Q4 - MedAvail Holdings will be opening an initial three SpotRx locations with InnovaCare Health in Florida in the fourth quarter of 2021. "Our physician-led models and innovative technology have placed InnovaCare on the forefront of healthcare transformation for 20 years. We are excited to be continuing this tradition through our partnership with MedAvail and embedding the SpotRx pharmacy in our clinics," said Connie Garcia, Pharm D., Pharmacy Manager of InnovaCare Health and Trinity Medical Center. "We believe that this collaboration with our skilled clinical teams will result in improved health outcomes for our patients - it is a game-changing technology and the future for pharmacy services."

16:03 EST Xencor sees ending 2021 with $575M-$625M in cash, cash equivalents - Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations into 2025. Xencor expects to end 2021 with between $575 million and $625 million in cash, cash equivalents, receivables and marketable debt securities.

15:40 EST ViacomCBS investigating issue impacting Paramount+ service - The Paramount+ Help Twitter account tweeted: "We are aware of issues impacting the service. We are investigating the issue and appreciate your patience." Reference Link

15:09 EST JetBlue reaches new tentative agreement on talks with TWU - JetBlue announced it has reached a new tentative agreement with the Transport Workers Union for JetBlue's inflight crewmembers. "We're pleased to share that the JetBlue and TWU negotiating committees have reached a new tentative agreement," said Ed Baklor, head of customer care and programs, JetBlue. "Our inflight crewmembers have been on the frontline supporting and protecting JetBlue's operation and our customers through the COVID-19 pandemic, and I am proud of the TWU and JetBlue teams for recognizing our environment and coming to the table with solutions. We look forward to bringing this contract to a vote with our inflight crewmembers."

14:22 EST Apple to accept App Store Connect developer submissions through the holidays - Apple said that, this year, it will be accepting submissions in App Store Connect throughout the upcoming holidays. "Make sure your apps are up to date and ready for the busiest season on the App Store," the company said in a post on its developer blog. "Due to anticipated high volume, plan to send time-sensitive submissions early. Please note that reviews may take longer to complete from November 24 to 28 and December 23 to 27." Reference Link

13:54 EST Golden Nugget Lake Charles to open new DraftKings retail sportsbook - Golden Nugget Casino Lake Charles and DraftKings jointly announced the launch of a new retail sportsbook slated to open on November 10, at 2pm at Golden Nugget Casino Lake Charles, pending licensure and regulatory approvals. "Louisiana sports fans age 21 and over will be able to place wagers on a variety of betting markets across professional, collegiate, and other sports leagues at the DraftKings Sportsbook located inside the Golden Nugget Casino Lake Charles. DraftKings will be launching its online sportsbook in Louisiana at a later date, pending aforementioned approvals. Once live, sports bettors in the state will be able to place bets online and via their mobile devices on the DraftKings Sportsbook app in permitted parishes," the companies stated.

12:34 EST Regenxbio treatment of Duchenne muscular dystrophy granted orphan status - Regenxbio's treatment of Duchenne muscular dystrophy was granted orphan status by the FDA, according to a post to the agency's website. Reference Link

12:04 EST AMD launches accelerators and EPYC processors, confirms Meta as CPU customer - AMD (AMD) held the virtual Accelerated Data Center Premiere, launching the new AMD Instinct MI200 series accelerators, which it calls "the world's fastest accelerator for high performance computing and artificial intelligence workloads," and provided a preview of the third Gen AMD EPYC processors with AMD 3D V-Cache. AMD also revealed new information about its next generation "Zen 4" processor core and announced the new "Zen 4c" processor core, both of which will power future AMD server processors and are "designed to extend the company's leadership products for the data center." AMD announced Meta (MVRS) is the latest major hyperscale cloud company that has adopted AMD EPYC CPUs to power its data centers. "AMD and Meta worked together to define an open, cloud-scale, single-socket server designed for performance and power efficiency, based on the 3rd Gen EPYC processor. Further details will be discussed at the Open Compute Global Summit later this week," AMD announced. Facebook (FB) is in the process of being rebranded as Meta. In midday trading, AMD shares are up $14.10, or 10%, to $150.44.

12:01 EST Nam Tai Property falls -10.6% - Nam Tai Property is down -10.6%, or -$2.47 to $20.92.

12:01 EST Eneti falls -16.4% - Eneti is down -16.4%, or -$2.33 to $11.88.

12:00 EST QuantumScape rises 18.3% - QuantumScape is up 18.3%, or $5.67 to $36.70.

11:40 EST Verizon names Manon Brouillette as CEO, Verizon Consumer Group - Verizon Communications announced the appointment of Manon Brouillette to Executive Vice President and CEO of Verizon Consumer Group effective January 1, 2022. She will succeed Ronan Dunne, who will take on the role of Strategic Advisor. Manon will report directly to Hans Vestberg, Verizon Chairman and CEO. "Manon brings a wealth of global expertise in consumer initiatives to Verizon, having scaled major brands with sustainable growth and exceptional customer-first experiences," Vestberg said. "Leveraging our investment in C-band and the pending Tracfone acquisition, Manon will continue to scale our Consumer business across home and mobile. We look forward to her transformative leadership as Verizon, poised for a high-growth 5G future, continues to disrupt the industry." Before joining Verizon as COO and Deputy CEO in July 2021, Manon was the President and CEO of Videotron.

11:36 EST Amazon's AWS plans to open second region in Canada - Amazon Web Services, an Amazon.com company, announced plans to open an infrastructure Region in Alberta, Canada, in late 2023/early 2024. The new AWS Canada West Region will consist of three Availability Zones at launch and join the existing AWS Canada Region in Montreal, which also consists of three Availability Zones, AWS said in a statement. It added that globally, AWS has 81 Availability Zones across 25 geographic regions, with plans to launch 27 more Availability Zones and nine more AWS Regions in Australia, Canada, India, Indonesia, Israel, New Zealand, Spain, Switzerland, and the United Arab Emirates. The upcoming AWS Canada West Region will enable even more developers, startups, and enterprises, as well as government, education, and nonprofit organizations, to run their applications and serve end users from data centers located in Canada, AWS also said. AWS also released an economic impact study estimating that the company's spending on construction and the operation of the new AWS Canada West Region and existing AWS Canada Region in Montreal will together create more than 5,000 new jobs with an estimated investment of over $17B in the local economies by 2037.

11:02 EST RYAH Group receives additional shipment order for UK-based clinical trial - RYAH Group announced that it has received an additional order for future shipments of hundreds of its proprietary RYAH Smart Dry Herb Inhalers and accessories to its United Kingdom-based industry partner following the recently-announced initial shipment. The ordered devices will be used by a growing number of participants of the major UK based clinical trial, previously announced by RYAH. The trial is planned to engage tens of thousands of United Kingdom patients over the next 5 years, and aims to focus on studying the safety and efficacy of plant-based therapies on chronic pain.

10:50 EST DLH Holdings appoints Maliek Ferebee as CHRO - DLH Holdings announced G. Maliek Ferebee has been appointed as Chief Human Resources Officer. In this role, Mr. Ferebee will be responsible for all aspects of the company's human resources operations, including talent acquisition and development, employee engagement, diversity and inclusion, performance management, compensation and benefits, and more. He will serve as a member of the Executive Leadership Team, working to ensure that the company has the talent and resources necessary to grow and enhance the business. Ferebee most recently served as Chief Human Capital Officer at Alion Science and Technology.

10:27 EST Tabula Rasa HealthCare appoints Brian Adams as co-president - Tabula Rasa HealthCare has announced important organizational changes that will enhance TRHC's corporate structure and reinforce strategic growth initiatives, with a focus on the Company's MedWise solutions. Effective immediately, Brian Adams will assume the role of Co-President of TRHC. He will retain the role of CFO while a national search is conducted to identify his replacement. Adams has served as the company's CFO since 2014. In his new role, Adams will oversee strategy, sales and account management, professional affairs, IT and software engineering, administrative services, and finance. This shift will help unify critical interrelated functions within TRHC and enable CEO, Chairman, and Founder Calvin Knowlton, PhD, to focus more broadly on the fulfillment of TRHC's mission to become the leading medication safety company. Adams will continue to report directly to Calvin Knowlton. Founder and President Orsula Knowlton, PharmD, MBA; COO Michael Greenhalgh, RPh; and CSO Jacques Turgeon, BPharm, PhD, will also continue to report to the CEO as well. As part of the organizational changes, Orsula Knowlton will take on responsibility for driving the company's diversity and inclusion efforts in addition to her work as Chief Marketing Officer and supporting the continued successful growth of TRHC's CareVention HealthCare in the PACE market.

10:16 EST Live Nation 'heartbroken' after Astroworld tragedy that left 8 dead - Live Nation said via Twitter that it is "Heartbroken for those lose and impacted at Astroworld. We will continue working to provide as much information and assistance as possible to the local authorities as they investigate the situation." At least eight people were killed and others were injured at the Houston music festival on Friday night, according to the report. Reference Link

10:03 EST Neuronetics, River Region Psychiatry enter exclusive partnership - Neuronetics and River Region Psychiatry Associates, a provider of mental health services in Alabama, Kentucky, Tennessee, and Georgia, announced today a partnership agreement under which Neuronetics will be the exclusive supplier of transcranial magnetic stimulation equipment to RRPA and its clinics. The first NeuroStar Advanced Therapy system will launch in the Pelham/Helena, Alabama community, with aspirations to expand into all clinics over the coming year.

10:00 EST CorePoint Lodging falls -12.4% - CorePoint Lodging is down -12.4%, or -$2.21 to $15.55.

10:00 EST Coty rises 11.9% - Coty is up 11.9%, or $1.11 to $10.40.

10:00 EST Ocwen rises 14.5% - Ocwen is up 14.5%, or $4.82 to $38.00.

09:50 EST Allegiance Bancshares trading resumes

09:48 EST Live Nation falls -5.7% - Live Nation is down -5.7%, or -$7.06 to $116.74.

09:48 EST CorePoint Lodging falls -12.4% - CorePoint Lodging is down -12.4%, or -$2.21 to $15.55.

09:48 EST Volta rises 13.3% - Volta is up 13.3%, or $1.25 to $10.67.

09:43 EST eHealth trading resumes

09:37 EST Marvel Universe titles arriving on Disney+ in IMAX's Expanded Aspect Ratio - Beginning November 12 - which also happens to be Disney+ Day - fans will be able to stream some of their favorite Marvel titles in IMAX's (IMAX) Expanded Aspect Ratio at home with IMAX Enhanced on Disney+ (DIS). According to Marvel's website, "IMAX's Expanded Aspect Ratio is 1:90:1, which offers up to 26% more picture for select sequences - meaning more of the action is visible on screen, just as the filmmakers intended. In the future, the collaboration will deliver even more enhanced audio and visual technology to Disney+, including immersive IMAX signature sound by DTS." The 13 titles available at launch include the Disney+ premiere of Marvel Studios' "Shang-Chi and The Legend of The Ten Rings" on November 12th as well as other MCU movies like "Iron Man," "Guardians of the Galaxy," "Guardians of the Galaxy Vol. 2," "Captain America: Civil War," "Doctor Strange," "Thor: Ragnarok," "Black Panther," "Avengers: Infinity War," "Ant-Man and The Wasp," "Captain Marvel," "Avengers: Endgame," and "Black Widow." Reference Link

09:29 EST Hop-on, Inc. enters LOI to acquire 30dB, terms not sisclosed - Hop-on is proud to announce a signed letter of intent to acquire 30dB, Inc. and integrate its technologies and operations into Digitalage, Hop-on's decentralized social media, entertainment, and journalism platform. This asset acquisition will provide a suite of technologies and capabilities in artificial intelligence, machine learning, natural language processing, topic classification, sentiment analysis, opinion mapping, content indexing, and text fingerprinting. These will be deeply integrated with Digitalage to provide greater search and discovery capabilities, drive better personalization, recommendations, and targeting, support detection of echo chambers, enable counter-bias efforts, and power the platform's new Dig Deeper feature that provides a socially responsible and user-friendly way to discover and explore opposing viewpoints and how they have changed over time, by geography, and within social groups. More information will be disclosed at a later date.

09:20 EST Blink Charging 'applauds' $1.2T bipartisan infrastructure bill - Blink Charging is proud to support the historic bipartisan infrastructure bill and applauds the Biden Administration and congressional lawmakers who are taking an important step to improve our nation's infrastructure, and accelerating the adoption of electric vehicles. "We are excited by the inclusion of $7.5 billion for EV infrastructure to build out our nation's EV network," stated Michael D. Farkas, Founder and CEO of Blink Charging. "The passage of the federal infrastructure package brings us one step closer to achieving significant funding for the development and deployment of EV infrastructure, a critical component to unlocking mass EV adoption, curbing transportation related emission and creating new jobs with this fast-growing industry. In addition, the bill aligns with the President's goal that half of the vehicles sold in the United States in 2030 will be zero-emissions vehicles and his aspiration to have 500,000 EV charging stations in place by that same year. This bill furthers the commitment we are already witnessing from local, regional, federal and utility partners who are committed to making EV charging a reality across the country. Thus far in 2021, Blink has been awarded nearly $25 million in existing EV infrastructure grants, rebates, and incentives. Due to Blink's unique owner and operator modality, we can amplify the impact of these grants, rebates, and incentives to create a robust ecosystem of EV infrastructure. In fact, due in part, to these opportunities, Blink has been able to accelerate efforts to widely deploy public EV charging stations across the country "With this legislation, the momentum we are seeing today is just the start of where the industry will go. This commitment by bipartisan lawmakers is pivotal in propelling the industry forward in a strategic and methodical manner, where public actions complement the efforts of private industry to develop the infrastructure required to realize significant and meaningful change for electric vehicles."

09:17 EST Microchip announces $4B stock repurchase program - Microchip announced that its Board of Directors has authorized the Company to purchase up to $4.0 billion of its common stock in the open market or in privately negotiated transactions including under Rule 10b-18. This new program replaces the Company's prior program to repurchase up to 30 million shares of common stock. Microchip expects to fund repurchases through available cash flow from operations after capital expenditures and dividend payments.

09:14 EST Mercury Systems completes acquisition of Avalex Technologies - Mercury Systems announced the completion of its acquisition of Avalex Technologies. Pursuant to the terms of the definitive agreement applicable to the acquisition, Mercury acquired Avalex for all cash, subject to net working capital and net debt adjustments. The acquisition was treated as an asset sale for tax purposes. The acquisition and associated transaction expenses were funded through a combination of cash on hand and Mercury's existing revolving credit facility. "We're pleased that this transaction was completed on schedule; the next step is executing a seamless integration," said Mark Aslett, Mercury's president and chief executive officer. "The acquisition is directly aligned with our strategy and will enable us to address and enable the growing demand for digitally converged solutions in the C4I and platform/mission management markets. We welcome the Avalex team to the Mercury family."

09:13 EST Prelude Therapeutics announces IND clearance for PRT2527 - Prelude Therapeutics announced that the United States Food and Drug Administration has accepted the Investigational New Drug, IND, application for its precision oncology candidate, PRT2527, which is designed to be a potent and selective CDK9 inhibitor. Prelude anticipates beginning a Phase 1 clinical trial of PRT2527 by year-end evaluating escalating doses of intravenous PRT2527 as a monotherapy in patients with selected solid tumors, including sarcoma, prostate cancer, breast cancer, and other cancers with genomic alterations that lead to MYC dependence. "Utilizing our internal discovery engine and expertise, we are focused on developing and advancing differentiated, optimal small molecule therapeutics to treat highly underserved patients with difficult to treat cancers. Our precision oncology approach seeks to identify those cancers vulnerable to mechanisms targeted by our product candidates, in the hopes of providing new options in the battle against these devastating diagnoses. I'm proud of the achievements of our Prelude team, as we now advance our fourth oncology candidate into clinical development. We look forward to providing updates on PRT2527 and our other clinical development programs in 2022," said Kris Vaddi, PhD, Chief Executive Officer.

09:12 EST EnWave announces club distribution for Moon Cheese in Canada - EnWave Corporation announces that its wholly-owned subsidiary, NutraDried Food Company, has secured a national 12-week distribution opportunity with a major warehouse club chain in Canada. Under the Club Promotion, NutraDried plans to ship 10 oz Gouda Moon Cheese to supply all of the Customer's club warehouses in Canada for the 12-week promotional term. The shipments are expected to be made in late December and into early January for the planned promotion at the beginning of 2022. EnWave believes that NutraDried will have multiple opportunities to win new rotations with the same customer in both the U.S. and Canada during the 2022 fiscal year and intends to pursue new growth in this strategic channel. NutraDried has expanded its channel strategy to include branded product, private label and bulk sales and plans to introduce new formats of Moon Cheese commercially to complement its current distribution. Further, there is continued broad interest from grocery, natural and convenience buyers in core Moon Cheese products as well as new formats scheduled to launch in 2022. NutraDried aims to confirm material new distribution in the coming months.

09:10 EST Philips announces results of analysis of CMS data on vascular intervetions - Royal Philips announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services data on the health outcomes of peripheral vascular interventions guided by intravascular ultrasound. The study was conducted independently by the Smith Center for Outcomes Research, with the results presented at the 2021 Transcatheter Cardiovascular Therapeutics meeting by Eric A. Secemsky, MD, Director of Vascular Intervention and Interventional Cardiologist at Beth Israel Deaconess Medical Center and Assistant Professor of Medicine at Harvard Medical School in Boston, Massachusetts. The study, supported by Philips, underlines the company's commitment to a strong evidence base for its innovations in the pursuit of better patient outcomes, enhanced patient and staff experiences, and lower cost of care. Numerous prospective studies have already shown the benefit of IVUS guidance in peripheral vascular interventions, making it a gold-standard imaging modality for this application. The new study results now show that the outcome observations from these prior studies apply directly to a broader peripheral arterial and peripheral venous intervention patient population, demonstrating strong support for the use of IVUS during peripheral interventions. Peripheral artery disease: a 32% reduction in major adverse limb events, including amputations, during lower extremity arterial interventions. The study looked at Medicare beneficiaries aged 65 years or older who underwent lower extremity arterial interventions between January 1, 2016, and December 31, 2019. Among 697,794 interventions, the investigators found a 32% reduction in major adverse limb events, such as amputations, over a median 425 days of follow-up. These findings were consistent across disease states, including critical limb ischemia and non-critical limb ischemia, as well as arterial segments such as the iliac, femoropopliteal and tibial. Peripheral artery disease develops when plaque builds up in the vessel wall and reduces blood flow to the limbs, most commonly the legs. It affects more than 8.5 million people in the USA. PAD symptoms include recurrent fatigue, leg pain, and foot or leg wounds that do not heal or heal very slowly. Critical limb ischemia is an advanced stage of PAD and is typically associated with high rates of cardiovascular events, amputations, and mortality. CLI patients have low survival rates, with 5-year mortality exceeding 50%. Chronic venous disease: a 31% reduction in repeat intervention, hospitalization, or death during iliofemoral venous stenting: Separately, the investigators examined Medicare beneficiary data for patients treated between January 1, 2017, and December 31, 2019, in multiple clinical settings, including hospital in-patient settings, hospital outpatient centers, and private office-based clinics, involving 20,984 individual patients. Of these, 72% underwent stenting guided by IVUS. When IVUS was used, there was a 31% reduction in the composite outcome of repeat intervention, hospitalization, or death. In addition, IVUS use reduced the risk of stent thrombosis, embolization and stenosis. Chronic venous disease is both a common and underappreciated problem impacting over 30 million Americans. Advanced CVD impacts over 6 million people in the USA and iliofemoral venous obstruction costs as much as USD 3 billion per year for ulcer care in advanced presentations.

09:09 EST Borqs Technologies granted land use right for 5G/IoT, EV Development - Borqs Technologies announced that the company's wholly owned subsidiary, Borqs Hong Kong Limited, has been granted land use rights for about 1.4M sq. ft. in Huzhou, China, a city located in the Yangtze River Delta. According to the grant agreement, the land use rights granted to Borqs's 5G Industrial Park are valued at $10.5M and will be developed in two phases. The first phase will be particularly for IoT and 5G technologies, the construction of which is planned to commence in 2022 and to be completed by the end of 2023. The second phase is planned to begin construction thereafter particularly for software and hardware products for the electric vehicle industry. The total construction space is targeted to be about 2.2M sq. ft. and is estimated to cost about $125M. Borqs is actively selecting and evaluating bids from developers for the industrial park. This project aligns the Company with future growth along the macroeconomic trends and the continuously increasing demands for connected solutions and achieving a zero carbon economy.

09:07 EST Conformis appoints James Paiva as new VP of US Marketing - Conformis (CFMS) announced that the vompany has appointed James Paiva as its new Vice President, VP, U.S. Marketing. Prior to joining Conformis, James spent the last 16 years with Johnson & Johnson (JNJ), working in a variety of roles of increasing responsibility in marketing, education, sales support, and business development.

09:07 EST Allegiance Bancshares, CBTX enter agreement to combine in all-stock merger - Allegiance Bancshares and CBTX announced that they have entered into a definitive agreement pursuant to which the companies will combine in an all-stock merger of equals to create a combined company with an equity market capitalization of approximately $1.5 billion and the 17th largest deposit market share in the State of Texas. Under the terms of the definitive merger agreement, Allegiance shareholders will receive 1.4184 shares of CBTX common stock for each share of Allegiance common stock they own. Based on the number of outstanding shares of Allegiance and CBTX as of November 5, 2021, Allegiance shareholders will own approximately 54% and CBTX shareholders will own approximately 46% of the combined company. Enhanced Profitability: On a pro forma basis, the combined company expects to deliver improved performance, with a targeted 2023 return on average assets of approximately 1.3%, return on average tangible common equity of approximately 12% and efficiency ratio of approximately 52%. Cost Synergy Opportunity: The merger is expected to generate an estimated $35.5 million of run-rate cost synergies by 2023, which represents approximately 15% of combined annual operating expense. Meaningful earnings per share and earnings accretion: The merger is targeted to deliver 40% and 17% accretion to CBTX's and Allegiance's earnings per share in 2023, respectively. Strong Combined Capital Levels: The combined company is expected to have a tangible common equity ratio of above 9.5% at closing. The combined company's expected strong capital ratios will support growth and capital management strategies. Reflecting the contribution both organizations bring to the combined company, the well-respected board and management team that is comprised of individuals with significant financial services experience will draw from both sides. Steve Retzloff, Chief Executive Officer of Allegiance, will be the Executive Chairman of the combined company; Bob Franklin, Chairman, Chief Executive Officer and President of CBTX, will be the Chief Executive Officer of the combined company; Ray Vitulli, President of Allegiance, will be the Chief Executive Officer of the combined bank; Paul Egge, Chief Financial Officer of Allegiance, will be the Chief Financial Officer of the combined company; Joe West, Chief Credit Officer of CBTX, will be the Chief Credit Officer of the combined bank; The board of directors of the combined company will initially be comprised of 14 directors - seven from Allegiance and seven from CBTX; Mr. Retzloff and Mr. Franklin will both be named directors of the combined company. The merger is expected to close early in the second quarter of 2022, subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals and approvals of shareholders of each company.

09:06 EST Blend Labs and Ocrolus announce strategic partnership - Ocrolus and Blend announced a strategic partnership which will embed Ocrolus' Human-in-the-Loop, or HITL, document analysis solution within the Blend platform to accelerate digital mortgage applications. Ocrolus' partnership with Blend will focus on document automation, initially on classifying documents and capturing data for mortgage applications and potentially extending into other business areas in the future.

09:04 EST Sage Group kicks off Sage Transform 2021 - Sage kicks off its revamped annual conference for Sage Intacct customers. The hybrid event will take place in Las Vegas, Nevada from November 8-12, 2021 - offering attendees both in-person and virtual experience options. Sage Transform, previously known as Sage Intacct Advantage and now in its 14th year, is dedicated to supporting Sage customers and partners and enabling them to thrive. With a new, broader focus on Sage solutions for medium-sized businesses, Sage Transform will give them the tools to do so through a mix of keynotes and breakout sessions focused on the latest best practices, vertical-specific industry insights, and breakthrough technology innovation for finance teams. With an expanded conference scope, customers and partners can learn more about the benefits of the Sage medium segment product portfolio and how these solutions make it easier to digitalize the most important components of their back-office operations.

09:04 EST Caribou Biosciences appoints Richardson-Heron to board, Khan as CBO - Caribou Biosciences (CRBU) announced the appointments of Dara Richardson-Heron, M.D., to its board of directors and Ruhi Khan as its chief business officer, CBO. Dr. Richardson-Heron has more than 25 years of leadership experience in the healthcare, corporate, nonprofit, and government sectors. Khan brings over 20 years of business development and investment management experience focused on the biotechnology and pharmaceutical industries. Richardson-Heron most recently served as Pfizer's (PFE) chief patient officer where she was responsible for developing the organization's global strategy to advance patient-focused programs. Khan most recently was the founder of an advisory firm that provided business development and finance advice to life science companies.

09:03 EST Brookfield closes growth fund with over $500M in committed capital - Brookfield Asset Management announced the closing of its growth fund, Brookfield Technology Partners II, with total equity commitments exceeding $500M.

09:03 EST Celsion receives approval for application to sell $1.5M New Jersey NOLs - Celsion Corporation announced it was notified by the New Jersey Economic Development Authority that the Company's application to sell $1.5 million of its unused New Jersey net operating losses for the tax year 2020 under the Technology Business Tax Certificate Transfer program has been approved the NJEDA's Board of Directors. The Company anticipates it will be able to transfer this credit to a qualified company and receive approximately $1.4 million of net cash proceeds. With this additional funding, the Company expects to report over $62 million in cash and investments at end of the third quarter ended September 30, 2021. This competitive program, administered by the NJEDA, enables qualified companies to sell their unused New Jersey net operating losses and R&D tax credits to unaffiliated, profit-generating corporate taxpayers in the state of New Jersey, up to a current maximum lifetime benefit of $20 million per company. This allows technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund more R&D, expand its workforce, and cover other allowable expenditures. Celsion is one of several qualifying biotechnology/technology companies to share in the funding this year.

09:01 EST Veeco announces repurchase of $111.5M of convertible senior notes - Veeco Instruments announced that it has entered into a privately negotiated note purchase agreement with Lynrock Lake LP under which Veeco will repurchase approximately $111.5 million in aggregate principal amount of Veeco's outstanding 2.70% Convertible Senior Notes due 2023 from Lynrock Lake Master Fund LP for cash consideration of approximately $115.6 million, and approximately $1.0 million of accrued and unpaid interest. The repurchase is expected to close on November 10, 2021, subject to customary closing conditions. Following the repurchase, approximately $20.2 million aggregate principal amount of Notes will be outstanding.

08:55 EST CBTX Inc trading halted, news pending

08:50 EST PDS Biotechnology license protein for treatment of TARP-associated cancers - PDS Biotechnology announced a licensing agreement with the National Cancer Institute, NCI, for intellectual property related to the NCI's proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein, TARP. Approximately 470,000 patients are diagnosed annually with TARP-associated cancers. In preclinical studies performed by PDS Biotech, the administration of PDS0102, the Versamune-TARP tumor antigen combination, led to the induction of large numbers of tumor targeted killer T-cells. "The highly promising proof-of-concept data presented earlier this year in the advanced HPV cancer trial solidifies our confidence in the Versamune technology to rapidly advance our pipeline into other types of debilitating cancers," said Dr. Lauren Wood, PDS Biotech's Chief Medical Officer. "We are excited about the potential of PDS0102, which leverages the Versamune platform to improve on the results reported in humans with the NCI's TARP antigen alone." The worldwide, non-exclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034.

08:48 EST Luckin Coffee to hold EGM to adopt amendments to memorandum - Luckin Coffee announced that it will convene an extraordinary general meeting of the Company at 10 a.m. on December 11, 2021, Beijing time. Holders of record of ordinary shares of the Company at the close of business on November 8, 2021 are entitled to notice of, to attend and vote at the EGM or any adjournment thereof. Holders of the American depositary shares representing ordinary shares of the Company who wish to exercise their voting rights for such underlying ordinary shares must act through the depositary of the Company's ADSs program, The Bank of New York Mellon. The purpose of the EGM is for the Company's shareholders to consider, and if thought fit, approve resolutions related to certain amendments to the Company's Fifth Amended and Restated Memorandum and Articles of Association. The resolutions proposed by the Board of Directors of Luckin Coffee are intended to protect the long-term viability of the Company and promote long term shareholder value. The Board has proposed the adoption of several resolutions, which serve different purposes and are together designed to ensure that no shareholder may directly or indirectly transfer shares of the Company to any Restricted Person (as defined below) and that any Restricted Person is not able to directly or indirectly transfer shares of the Company, or to exercise voting power with respect to the shares of the Company that such Restricted Person legally or beneficially owns, directly or indirectly. The Board fully supports these proposals and recommends that shareholders and holders of the ADSs vote in favor of these proposals.

08:47 EST Rush Street Interactive fully launches BetRivers online sportsbook in AZ - Rush Street Interactive announced that its award-winning BetRivers online sportsbook is fully launched in Arizona. Sports fans aged 21 and over can now register, deposit funds, wager, and withdraw payouts quickly and securely from the BetRivers Sportsbook app for iOS and Android. The BetRivers online sportsbook offers thousands of betting options on various leagues, games, and players, as well as other innovative features including betting tips, an advanced stats center and player search functionality, a wide library of live streaming content and real time game tracker visualizations. RSI's mobile sportsbook app was recently rated #3 out of 35 mobile sportsbook apps in the United States market last month by independent gaming research firm Eilers & Krejcik. "We are excited to bring our industry leading gaming platform to Arizona, marking the second state in as many months where we have launched online sports betting," said Richard Schwartz, Chief Executive Officer of RSI. "Moreover, with the sports calendar in full swing, and with the Arizona Cardinals near the top of the NFL, BetRivers could not be arriving in Arizona at a better time. We invite Arizonans to experience the huge volume of betting content and first-rate customer service we have to offer and see why BetRivers is the preferred sportsbook of more and more Americans." In August, RSI announced a multi-year market access partnership with the Arizona Rattlers, a long-tenured professional indoor football franchise in Phoenix. The Arizona Rattlers are one of the most accomplished professional sports teams in Arizona and are coming off a successful 2021 season where the team advanced to the Indoor Football League's championship game, the United Bowl. Mr. Schwartz said, "We are grateful for the trust and partnership of the Arizona Rattlers as well as the Arizona Department of Gaming, and look forward to delivering responsible, player-first entertainment to sports enthusiasts across the state."

08:46 EST Cellectar Biosciences sees cash runway into 2H23 - As of September 30, 2021, the company had cash and cash equivalents of $40.3 million compared to $57.2 million at December 31, 2020. Cash used in operating activities was approximately $18.1 million during the nine months ended September 30, 2021 as compared to $10.1 million during the nine months ended September 30, 2020.

08:44 EST Gulf Resources announces conference call to discuss compensation program - Gulf Resources announced a conference call to discuss the new compensation program initiated by the Company to align the interests of its Chairman and senior management with that of its shareholders. For several years, the Company has been dissatisfied with its financial performance and with its inability to take cash from China to pay dividends and buy back shares. It has been seeking a way of attempting to align the interests of its shareholders with that of its management. The Company has created a new compensation program, that includes: The Chairman and top three executives repay most or all of their cash compensation earned during the past approximately 11 1/2 years. The Chairman and CEO receive no cash compensation. The COO and CFO have their cash compensation reduced by approximately 82%. In exchange, the top executives, but not the Chairman, would receive shares of stock. By repaying most or all of their cash compensation for the past approximately 11 1/2 years and reducing or eliminating their current cash compensation, senior management will only do well if the price of the shares of Gulf Resources does well.

08:43 EST Toll Brothers, Sundance Bay enter joint venture to develop Broad & Noble - Toll Brothers, through its Toll Brothers Apartment Living rental division, and Sundance Bay announced the formation of a new joint venture to develop Broad & Noble, a 344-unit, mixed-use rental apartment community in Philadelphia, Pa. The project is being financed through a $100.2M construction loan facility from Wells Fargo. The debt and equity were arranged by Toll Brothers' in-house Finance Department. Toll Brothers Apartment Living will manage the development, marketing, and property management. Broad & Noble will consist of 344 rental apartments in an 18-story high-rise building. The project includes 106 underground parking spaces, 16,176 square feet of amenity space, and 10,440 square feet of street-level retail.

08:41 EST Corcept Therapeutics commences tender offer to purchase up to 10M shares - Corcept Therapeutics announced that it has commenced a modified Dutch Auction tender offer for the purchase of up to 10 million shares of Corcept's common stock, par value $0.001 per share or such lesser number of Shares as are properly tendered and not properly withdrawn, at a price not greater than $23.75 per Share nor less than $20.75 per Share, to be paid to the seller in cash less any applicable withholding taxes. The tender offer is made in accordance with the terms and subject to the conditions described in the offer to purchase, the related letter of transmittal and other related materials, as each may be amended or supplemented from time to time. The closing price of the Shares on The Nasdaq Stock Market on November 5, 2021, the last full trading day before the start of the tender offer, was $20.68 per Share. The tender offer is scheduled to expire one minute after 11:59 P.M., New York City Time, December 7, 2021, unless the offer is extended or terminated. Corcept believes that the repurchase of Shares pursuant to the tender offer is consistent with its long-term goal of maximizing stockholder value and that the tender offer is an efficient way to give stockholders the opportunity to receive a return of their investment by tendering some or all of their Shares.

08:41 EST Zix to be acquired by OpenText for $8.50 per share in cash - Zix announced that it has entered into a definitive agreement to be acquired by OpenText for $8.50 per share in cash, representing an enterprise value of $860M. Under the terms of the agreement, an OpenText subsidiary will commence a tender offer for all outstanding shares of Zix common stock at a price of $8.50 per share in cash, representing a premium of 16% to the volume-weighted average closing price of Zix common stock for the 20 trading days prior to October 18, when news reports appeared regarding a potential transaction. Closing is subject to the tender of two-thirds of Zix's common shares outstanding as well as customary regulatory approvals and other customary conditions, and the transaction is expected to close within 90 days of this announcement. Zix's largest shareholder, an affiliate of True Wind Capital, has agreed, subject to satisfaction of certain conditions, to convert its Series A Preferred Shares into common shares and to tender those shares in the tender offer. Zix's executive officers and certain directors have likewise agreed to tender their common shares in the tender offer.

08:40 EST Baxter reveals data from Sharesource platform supporting home dialysis option - Baxter International announced new data showing kidney patients may experience a survival rate nearly two-times higher and a prolonged time to an adverse event and hospitalization when the Sharesource remote patient management digital health platform is used to help manage home automated peritoneal dialysis .The new data was presented during the American Society of Nephrology's annual Kidney Week, Nov. 4-7, in abstract session, "Remote Monitoring of Patients with APD May Improve Clinical Outcomes: Analysis by Competing-Risk Regression Models,". The randomized controlled trial of 815 kidney patients spanning 22 hospitals in Mexico evaluated mortality and first AE or first hospitalization for kidney patients on home APD with and without the aid of remote patient management digital health. "The study indicates Sharesource's role in supporting clinically meaningful outcomes that help kidney patients gain access to home dialysis and remain on therapy for as long as possible," said Peter Rutherford, MB BS, PhD., vice president Medical Affairs, Baxter Renal Care. "As we move through the COVID-19 pandemic, digital health is demonstrating how it may support healthcare professionals to improve clinical outcomes and allow patients to remain at home with reduced unplanned hospital visits."

08:39 EST Ageagle Aerial Systems announces launch of MicaSense's Altum-PT - AgEagle Aerial Systems announced the launch of MicaSense's most pioneering drone sensor innovation, to date: Altum-PT. MicaSense's, an AgEagle company, Altum-PT is a three-in-one solution for advanced remote sensing and agricultural research. It integrates an ultra-high resolution panchromatic imager, a built-in 320X256 radiometric thermal imager and five discrete spectral bands to produce synchronized outputs such as RGB color, crop vigor, heat maps and high resolution panchromatic. Commenting on the new product launch, Brandon Torres Declet, AgEagle's Chief Executive Officer, said, "We are very proud of the success we have achieved through market adoption of our legacy products and are excited about again raising the bar on drone sensor excellence through our newest market entrants, RedEdge-P and now the Altum-PT. Both sensors represent revolutionary leaps forward in multispectral technology and should serve to fuel even greater future growth for our Company moving forward. With global distribution in over 70 countries worldwide, we are pleased to provide our valued customers with the tools they require to achieve their respective objectives through our novel advancements in drone sensors and their expanding applications."

08:37 EST Selecta Biosciences announces data from Phase I SEL-399 AAV empty capsid study - Selecta Biosciences announced top-line results from a joint Selecta and AskBio Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTOR platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8, AAV8, serotype capsid used in gene therapies. At day 30, in those subjects administered a single 0.3 mg/kg dose of ImmTOR, Selecta observed a median anti-AAV8 neutralizing antibody titer of 1:5, a 250-fold lower level than that observed in subjects dosed with AAV8 capsid alone. "We believe these data demonstrate ImmTOR's potential to address one of the biggest current limitations in gene therapy, the inability to re-dose life-saving gene therapies due to the formation of neutralizing antibodies against AAV capsids," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "We observed that a single 0.3 mg/kg dose of ImmTOR mitigated the formation of neutralizing antibodies through 30 days. We believe these results, combined with our compelling preclinical data where we observed that two additional monthly doses of ImmTOR inhibited the formation of neutralizing antibodies in non-human primates through at least 84 days and in mice through at least 168 days, suggests that ImmTOR has the potential to enable the redosing of life-altering gene therapies. With our extensive experience with monthly dosing of ImmTOR in humans through the SEL-212 asset in Phase 3 we look forward to leveraging these exciting and novel findings in the clinic across our wholly owned gene therapy pipeline and alongside our world class gene therapy partners to achieve our goal of improving the lives of those living with monogenic diseases." Key findings include: No Serious Adverse Events were reported. All treatment-related adverse events were expected for ImmTOR, readily monitorable, and transient; AAV8 empty capsids elicited a strong immune response; Median day 30 titers of neutralizing anti-AAV8 antibodies were 1:25 and 1:5 in the 0.15 mg/kg and 0.3 mg/kg ImmTOR cohorts, respectively; Median day 30 titers of neutralizing anti-AAV8 antibodies were 50-fold and 250-fold lower in the 0.15 mg/kg and 0.3 mg/kg ImmTOR cohorts, respectively; At 30 days, of subjects who received 0.3 mg/kg of ImmTOR, 6 of 6, or 100%, exhibited an anti-AAV8 neutralizing antibody titer of 1:25 or less, and 4 of 6 or 67% had a titer of 1:5 or less; At 30 days, of subjects that received 0.15 mg/kg of ImmTOR, 6 of 9, or 67%, exhibited an anti-AAV8 neutralizing antibody titer of 1:25 or less, and 2 of 9, or 22% had a titer of 1:5 or less; By comparison, of subjects that received AAV8 empty capsid alone, only 1 of 8, or 12.5%, had a neutralizing antibody titer of 1:25 or less at 30 days, and no subjects had a titer of 1:5 or less; and At 90 days 2 of 6 subjects in the 0.3 mg/kg cohort were observed to have sustained control of neutralizing antibodies with titers of 1:25 or less; Consistent with preclinical data, we observed that the single dose ImmTOR cohorts saw delayed formation of neutralizing antibodies eventually reaching similar median levels of neutralizing antibodies to the control group by day 90.

08:37 EST McAfee to be acquired by investor group for $26.00 per share in all-cash deal - McAfee announced it has entered into a definitive agreement to be acquired by an investor group led by Advent International and Permira Advisers, Crosspoint Capital, Canada Pension Plan Investment Board, GIC Private and a wholly owned subsidiary of the Abu Dhabi Investment Authority. As part of the transaction, the Investor Group will acquire all outstanding shares of McAfee common stock for $26.00 per share in an all-cash transaction valued at approximately $12B on an equity value basis, and over $14B on an enterprise value basis after giving effect to repayment of McAfee debt. The purchase price represents a premium of approximately 22.6% over McAfee's closing share price of $21.21 on November 4, the last trading day prior to media reports regarding a potential sale of McAfee. Upon completion of the transaction, the Investor Group will take ownership of McAfee. As a privately held company, McAfee will continue as a pure-play consumer cybersecurity company following the sale of McAfee's Enterprise business, and the associated one-time dividend of $4.50 per share, to private equity firm Symphony Technology Group for $4B, which closed on July 27. Under the terms of the agreement, which has been approved by the McAfee board of directors, McAfee shareholders will receive $26.00 in cash for each share of common stock they own. The transaction is expected to close in the first half of 2022, subject to customary closing conditions, including, among others, approval by McAfee shareholders, receipt of regulatory approvals, and clearance by the Committee on Foreign Investment in the United States. Intel Americas and certain funds affiliated with TPG Global have entered into a voting agreement pursuant to which they have agreed, among other things, to vote their shares of company stock in favor of the transaction, subject to certain conditions. The voting support under the voting agreement ceases automatically if the merger agreement is terminated or if the McAfee board makes an adverse recommendation change. These stockholders currently represent approximately 67.9% of the current outstanding voting power of the McAfee common stock. Under the terms of the definitive merger agreement, McAfee's board and advisors may actively initiate, solicit and consider alternative acquisition proposals during a 45-day "go shop" period. McAfee has the right to terminate the merger agreement to accept a superior proposal during the go-shop period, subject to the terms and conditions of the merger agreement. There can be no assurances that this process will result in a superior proposal, and McAfee does not intend to disclose developments with respect to this solicitation process unless and until McAfee's Board makes a determination requiring further disclosure. The buyer entity in the merger, Condor BidCo, has obtained equity financing and debt financing commitments for the purpose of financing the transactions contemplated by the merger agreement. Funds advised by the Investor Group have committed to capitalize parent at the closing of the merger with an aggregate equity contribution equal to $5.2B on the terms and subject to the conditions set forth in signed equity commitment letters. The Investor Group has obtained a commitment to provide debt financing consisting of a $6.66B first lien term loan facility, a $1B first lien cash flow revolving facility and a $2.32B senior unsecured bridge facility, subject, in each case, to customary conditions. PSP Investments Credit USA LLC and investment funds managed by Neuberger Berman have agreed to provide the Investor Group with preferred equity financing with an aggregate liquidation preference of up to $800M, subject to customary conditions. Upon completion of the transaction, McAfee common stock will no longer be listed on any public securities exchange.

08:35 EST OSI Systems division Spacelabs Healthcare receives order valued at $5M - OSI Systems announced that its Healthcare division, Spacelabs Healthcare, received an order valued at approximately $5M to provide patient monitoring solutions to a Northwestern U.S. based hospital. The Company is expected to provide Xhibit Central Stations, Qube and Qube Mini transport patient monitors, Intesys Clinical Suite, and related accessories. "We are excited to receive this order and look forward to supporting this hospital's installation of our advanced solutions for critical care," commented Deepak Chopra, OSI Systems' Chairman and CEO.

08:34 EST OpenText to acquire Zix for $860M - OpenText (OTEX) announced that it has entered into a definitive agreement to acquire Zix Corporation, a leader in SaaS-based email encryption, threat protection and compliance cloud solutions for Small and Medium-sized Businesses. Highlights include: Tender offer to be commenced for all outstanding Zix common stock (including shares of common stock issued upon conversion of Zix's Series A Preferred Stock) shares for $8.50 per share in cash; Total purchase price of approximately $860M, inclusive of Zix's cash and debt; Total purchase price is approximately 3.5x TTM Zix GAAP revenues; Expect meaningful expansion of cloud revenues, adjusted EBITDA and cash flows in OpenText's Fiscal 2023; Expect Zix Annual Recurring Revenues of greater than 90%; Immediately accretive upon closing to adjusted EBITDA, and targeting to be on the OpenText operating model within 12-18 months of closing;Funded with OpenText's existing cash on hand; Expect the transaction to close within 90 days of this announcement; Financial projections and target models will be provided on the earnings call following the closing of the transaction.

08:33 EST Wyndham announces agreement with Matt Braun for five new hotels in Oregon - Wyndham Hotels & Resorts announced an agreement with developer Matt Braun of Braun Hospitality, for five new Microtel Inn & Suites by Wyndham hotels in Oregon. These hotels join the approximately 300 Microtel hotels across the U.S. and over 80 Microtel properties in the company's U.S. pipeline. The agreement provides for new Microtel Inn & Suites by Wyndham properties in the exciting Oregon growth markets of Florence, Ashland, Salem, Bend and Hood River. Braun Hospitality, the hotels' ownership, will provide the development oversight and expertise for the planning, design, entitlement, and construction management of the five new properties.

08:32 EST McAfee to be acquired by investor group for $26.00 per share

08:31 EST OpenText to acquire Zix for $860M

08:30 EST Biotech Acquisition Company (Class A Stock) trading resumes

08:28 EST Fulgent and Helio announce new data regarding HelioLiver performance - Helio Health and its commercial partner, Fulgent Genetics, announced new data at AASLD demonstrating the performance of HelioLiver in detecting early hepatocellular carcinoma, or HCC. At 91% specificity, the sensitivity of HelioLiver was 76% in early-stage HCC and 85% in overall HCC1, demonstrating superior performance over alpha fetoprotein, or AFP, alone and the GALAD model. HelioLiver is a multi-analyte blood test that utilizes both cell-free DNA, or cfDNA, methylation patterns and protein tumor markers to detect early-stage HCC with high accuracy. HelioLiver has the potential to reduce morbidity and mortality in HCC patients as there are more curative treatment options when the cancer is found at earlier stages. A highly sensitive blood test can drive patient adherence to surveillance guidelines and provide a more convenient and cost-effective way to detect HCC.

08:28 EST Nicholas Financial enters $175M senior secured credit facility - Nicholas Financial announced that on November 5, 2021 the company entered into a senior secured credit facility pursuant to a loan and security agreement with Wells Fargo Bank, N.A., as agent, and the lenders that are party thereto. The prior credit facility pursuant to a credit agreement with Ares Agent Services, L.P. was paid off in connection with entering into this credit facility. Pursuant to the credit agreement, the lenders have agreed to extend to Nicholas Financial a line of credit of up to $175,000,000. The availability of funds under the credit facility is generally limited to an advance rate of between 80% and 85% of the value of eligible receivables, and outstanding advances under the credit facility will accrue interest at a rate equal to the Secured Overnight Financing Rate plus 2.25%. The commitment period for advances under the credit facility is three years. Additionally, in the quarter ending December 31, 2021, Nicholas Financial is planning to recognize approximately $1.9 million of expenses associated with the origination of its prior credit facility. Management believes that the long-term cost benefits provided by the credit facility with Wells Fargo will outweigh this one-time, non-cash impact. In connection with the refinancing and as required under GAAP, Nicholas Financial expects to recognize a non-cash charge of approximately $1.9 million in the quarter ending December 31, 2021, representing the unamortized portion of debt origination costs associated with its prior credit facility. Management believes that the long-term cost benefits provided by the credit facility with Wells Fargo will outweigh this one-time, non-cash impact.

08:27 EST Nano Dimension announces DragonFly IV 3D-printer, FLIGHT software platform - Nano Dimension introduces its new DragonFly IV printer and FLIGHT software platform. The new DragonFly IV system, combined with FLIGHT software, delivers new levels of quality, efficiency, and print resolution in the 3D printed electronics sector - providing increased flexibility to design any 3D geometry and create innovative new products. DragonFly IV is a Dielectric & Conductive-Materials Additive Manufacturing System aimed for fabrication of High-Performance Electronic Devices by depositing the proprietary materials simultaneously, while concurrently integrating in-situ capacitors, antennas, coils, transformers, and electro-mechanical components.

08:26 EST Acurx announces microbiome data from its Phase 2a clinical trial for CDI - Acurx Pharmaceuticals announced that new microbiome data from its Phase 2a clinical trial for C. difficile Infection, or CDI, were presented at the 9th International C. diff Conference & Health Expo entitled: "Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect?" The presentation was made on November 5, 2021, by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy and the Principal Investigator for microbiome aspects of the ibezapolstat clinical trial program. Phase 2a data demonstrated complete eradication of colonic C. difficile by day three of treatment with ibezapolstat as well as the observed overgrowth of healthy gut microbiota, Actinobacteria and Firmicute phyla species, during and after therapy. Very importantly, emerging data show an increased concentration of secondary bile acids during and following ibezapolstat therapy which is known to correlate with colonization resistance against C. difficile. Additionally, a decrease in primary bile acids and the favorable increase in the ratio of secondary-to-primary bile acids suggest that ibezapolstat may reduce the likelihood of CDI recurrence when compared to vancomycin.

08:25 EST Crinetics presents new data from OLE trial of paltusotine - Crinetics Pharmaceuticals announced that new data from ACROBAT Advance, the ongoing open label extension, OLE, trial of paltusotine in patients with acromegaly, will be featured in a poster presentation at the annual Society for Endocrinology BES congress in Edinburgh, Scotland. Patients who completed either of the Phase 2 ACROBAT Edge or Evolve studies including a 4-week washout period were eligible to enroll in Advance. ACROBAT Edge and Evolve were two separate Phase 2 studies that enrolled a broad cross section of acromegaly patients, including those who were biochemically controlled on an injected somatostatin receptor ligand, as well as those who were uncontrolled on treatment regimens that included an SRL. Through August 31, 2021, 84% of eligible ACROBAT participants had opted to continue into the Advance OLE. "These promising long-term data further support our thesis that once daily oral paltusotine has the potential to replace injected peptide depots as the standard-of-care for acromegaly," added Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "They also give us added confidence as we advance through our Phase 3 PATHFNDR program, which aims to support the registration of paltusotine for all acromegaly patients who require pharmacotherapy."

08:24 EST Jacobs makes strategic investment in HawkEye 360 - Jacobs has made a strategic investment in HawkEye 360, the industry leader in radio frequency geoanalytics, providing commercially available precise mapping of global RF emissions. Jacobs and HawkEye 360 have also entered into a distribution arrangement under which Jacobs will enhance its digital intelligence suite of technologies and solutions with HawkEye 360's RF spectrum analytics and collection automation offering.

08:23 EST Daikin Industries goes live with Manhattan SCALE - Daikin (DKILY) has officially switched on the ignition to Manhattan Associates' (MANH) Manhattan SCALE warehouse management solution, WMS, at its new Daikin Park distribution center in Warwick Farm, Sydney. Manhattan SCALE serves as an all-encompassing automated warehouse solution to optimize manufacturing, fulfilment, and dispatch operations at Daikin Park - the largest air conditioning DC in Australia. "By upgrading the Daikin Park facility with Manhattan SCALE, we are now able to take back full control of our operations by having better access to warehouse, transport & logistics and customer data. During a high-pressure time, like the one we are currently experiencing with the pandemic, this information has been extremely valuable. Having this kind of visibility allows us to make better business decisions to improve efficiencies and customer experiences," said Michael Trad, head of SCM & IT, ANZ at Daikin. "Since going live with the Manhattan system, we are able to track our products at every point throughout the supply chain. This enhancement has significantly boosted the level of information we can share with our delivery drivers and customers, so that they are kept informed about all aspects of their orders."

08:22 EST ATI Physical Therapy acquires Hope Rehab Katy - ATI Physical Therapy announced that the company has acquired Hope Rehab Katy in Katy, TX, which extends its footprint into the Houston market. The addition of Hope Rehab Katy's two-clinic practice strengthens ATI's Texas portfolio and builds on existing clinics in Dallas, Fort Worth, Austin, and San Antonio.

08:21 EST LifeMD launches virtual care platform across 50 states - LifeMD announced the launch of its virtual care platform - which uses telemedicine to connect patients directly with a doctor. The LifeMD virtual care platform combines telehealth technology with in-house physicians to provide care across all 50 states. "American healthcare is irretrievably broken. Twenty-five percent of adults in America do not have a primary care physician, and many who do wait months just for appointments, then spend hours in waiting rooms and worry about affording their medical bills. Our new virtual care platform addresses this full-blown crisis - and offers a solution," said LifeMD CEO, Justin Schreiber. LifeMD is strategically sequencing the rollout of the virtual care offering. In the initial phase - commencing today - the platform will be available by invitation. The final stage of the launch, commencing nationwide access for the general public, is set for January 1, 2022.

08:19 EST I-Mab announces strategic collaboration with Roche Diagnostics - I-Mab (IMAB) announced that the Company has entered into a strategic collaboration with Roche (RHHBY) Diagnostics, a global leader in in vitro diagnostics industry, to co-develop companion diagnostics, or CDx, solutions for I-Mab's innovative pipeline, at the Fourth China International Import Expo in Shanghai. Under this collaboration, the Company and Roche Diagnostics will jointly develop companion diagnostics solutions for the innovative assets under development by I-Mab to accelerate the research and development process of innovative biologics with cutting-edge diagnosis and treatment technologies.

08:19 EST Medtronic targets net zero carbon emissions by FY2045 - Medtronic announced its ambition to achieve net zero carbon emissions by fiscal year 2045 across its operations and value chain (scopes 1, 2, and 3) to accelerate efforts to combat climate change. The announcement comes during the 2021 United Nations Climate Change Conference, where world leaders are focusing on collectively cutting greenhouse gas emissions and limiting global warming to 1.5 degrees Celsius compared to pre-industrial levels.

08:18 EST Brooks Automation announces new agreement with QTC Management - Brooks Automation (BRKS) announced that its newly branded Azenta Life Sciences business has been contracted by QTC Management, a Leidos company (LDOS), to provide the storage and distribution of vaccines to the U.S. Department of Defense. Earlier this year, QTC was awarded the prestigious Reserve Health Readiness Program III contract, under which they will provide commercial health services to all U.S. military reserve forces. Azenta will work with QTC and the Defense Health Agency to ensure the safe, reliable supply of vaccines for service members. This includes the provision of temperature controlled secure storage for active vaccines, and timely shipment and delivery of vaccines to QTC clinics and temporary events located across all 50 U.S. States, territories, Washington DC, and locations in Germany.

08:17 EST Snap One extends partnership with Josh.ai with strategic development - Snap One is expanding the presence and availability of artificial intelligence in the home through an enhanced driver as well as an exclusive distribution agreement with Josh.ai. Josh.ai and Snap One have worked on new driver enhancements to create a better experience for customers. Immediately available on the online driver database is an updated Josh.ai driver that is now Control4 Certified and SDDP capable. The driver can now import Control4 advanced lighting scenes and offers deeper integration with music streaming services through Control4. "Natural language voice processing, tight integration with Control4, and a focus on privacy makes Josh.ai the ideal addition for customers looking to add voice to their Control4 system. We are excited to make Josh.ai products more accessible to our Control4 Partners and for this first step in a long and successful partnership with the Josh.ai team," John Heyman, CEO of Snap One.

08:16 EST Biotech Acquisition and Blade announce definitive merger agreement - Biotech Acquisition, a company affiliated with SPRIM Global Investments, and Blade Therapeutics, a biopharmaceutical company based in South San Francisco, California, announced that they have entered into a definitive merger agreement. Upon the closing of the transaction, which is anticipated to occur in the Q1 of 2022, the combined company will be renamed Blade Biotherapeutics, and is expected to be listed on Nasdaq under the symbol "BBTX." The transaction is expected to provide a pro forma cash balance of approximately $254.3M to the combined company, before deducting estimated transaction expenses of $25.0M and including an approximately $24.3M private investment in public equity, or PIPE, priced at $10.00 per share and $230.0M of net cash held in BAC's trust, assuming no redemptions by BAC's existing shareholders. PIPE financing is anchored by institutional investors, including Deerfield Management, Pfizer Ventures, Bristol Myers Squibb, MPM Capital and Osage University Partners. As part of the transaction, the outstanding equity of Blade will be converted into equity of the combined company. The net proceeds from the transaction are expected to be used to support clinical, manufacturing and preclinical activities for the combined company's lead product candidates, development of additional pipeline programs, and for working capital and general corporate purposes.

08:15 EST Seelos Therapeutics: FDA approves NDA, grants Fast Track for SLS-005 - Seelos Therapeutics announced that the U.S. FDA has accepted Seelos' Investigation New Drug application to study SLS-005 for the treatment of spinocerebellar ataxia. The FDA has also granted the program Fast Track designation in the U.S. for SCA, and SLS-005 has previously received Orphan Drug designation for spinocerebellar ataxia type 3 from the FDA and from the European Medicines Agency in the EU.

08:12 EST Uber, Serve Robotics expand partnership - Serve Robotics announced a partnership with Uber Technologies. The on-demand robotic delivery service will be available to Uber Eats customers starting in Los Angeles early next year.

08:10 EST Talis Biomedical granted FDA EUA for Talis One COVID-19 Test System - Talis Biomedical Corporation announced that the U.S. Food and Drug Administration has granted Emergency Use Authorization for its Talis One COVID-19 Test System - a nucleic acid amplification test. The Talis One COVID-19 test runs on an integrated system that includes a compact instrument, self-contained, single-use test cartridges and software for reporting results. Designed for use in a variety of healthcare and congregate settings, the Talis One system enables sample-to-answer molecular testing in less than 30 minutes. In a clinical study, the Talis One COVID-19 Test System demonstrated 100% concordance with the comparator test results, including both the positive and negative percent agreements2. All samples were collected and tested in point-of-care settings. The Talis One COVID-19 Test System targets two genes, ORF1ab and N, to optimize sensitivity and the inclusion of variants. The ORF1ab and N gene were selected for their conserved nature and their unique sequence specific for SARS-CoV-2. Designed for cloud connectivity, the instrument is being further developed to enable easy results sharing and simplified patient data management in the future. Development of the Talis One COVID-19 Test System was supported by the NIH Rapid Acceleration of Diagnostics RADxSM initiative and has been funded in part with federal funds from National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92020C00010. As a participant in the RADx program, the company assessed the impact of ten distinct COVID-19 variants demonstrating high sensitivity of detection3. At the time of testing in June, the emerging Delta variant was not available to be included in the study. Subsequently, the company conducted a separate bioinformatic analysis for the Delta variant as well as testing in vitro transcript samples to support its EUA submission. In testing for all these variants, including Delta, no loss in sensitivity or impact on the Talis One COVID-19 Test System's performance was detected4. Talis is continuing to monitor new COVID variants as they arise.

08:09 EST Phathom Pharmaceuticals provides clinical, regulatory updates - The U.S. Food and Drug Administration accepted NDAs for two convenience packs containing vonoprazan-based treatment regimens for adults with H. pylori infection: vonoprazan in combination with amoxicillin and clarithromycin and vonoprazan in combination with amoxicillin. The NDAs were granted Priority Review designation with a Prescription Drug User Fee Act target action date of May 3, 2022. Phathom submitted the NDAs to the FDA on September 3, 2021. The FDA previously designated vonoprazan dual and triple therapy as qualified infectious disease products which, if approved, will provide vonoprazan five additional years of regulatory exclusivity. If approved, the U.S. commercial launch for vonoprazan dual and triple therapy is anticipated in the second half of 2022. Vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal Phase 3 trial evaluating vonoprazan for the healing and maintenance of healing of erosive esophagitis. Based on these results, Phathom expects to submit an NDA in the first quarter of 2022 seeking the following indications for vonoprazan: healing of all grades of EE and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn. Topline results from the Phase 2 PHALCON-NERD on-demand trial evaluating various doses of vonoprazan as an on-demand therapy for patients with non-erosive reflux disease are expected in the first quarter of 2022.

08:07 EST Phathom Pharmaceuticals expects cash to meet requirements into mid-2023 - As of September 30, 2021, cash and cash equivalents were $224.6 million. Cash and cash equivalents combined with the future drawdown of the remaining $100 million under the Loan Agreement are expected to be sufficient to meet anticipated cash requirements into mid-2023 based on current operating plans.

08:07 EST Chinook Therapeutics announces upcoming milestones - Atrasentan: Enrollment of the phase 3 ALIGN trial of atrasentan continues to progress with the activation of new trial sites and expansion into additional countries. Chinook expects to report topline data from the six-month interim proteinuria endpoint analysis in 2023 to support an application for accelerated approval under Subpart H in the U.S. Chinook continues to enroll all four cohorts of the phase 2 AFFINITY basket trial, including patients with lower proteinuria IgAN, focal segmental glomerulosclerosis, Alport syndrome and diabetic kidney disease in combination with SGLT2 inhibitors. Chinook expects to present data from the IgAN patient cohort of this study in the first half of 2022, with data from one or more additional cohorts expected in the second half of 2022. BION-1301: Chinook expects to present additional data from the ongoing phase 1/2 trial of BION-1301 in patients with IgAN and provide an update on planned later-stage clinical trials of BION-1301 in the first half of 2022. CHK-336: Chinook has completed IND-enabling toxicology studies and is advancing CHK-336 towards IND submission and initiation of a phase 1 clinical trial in healthy volunteers in the first half of 2022.

07:55 EST Biotech Acquisition Company (Class A Stock) trading halted, news pending

07:48 EST Eneti announces public offering of common shares - Eneti announced that it intends to offer, issue and sell to the public $200 million of shares of its common stock, par value $0.01 per share, through an underwritten public offering. The net proceeds of the Offering are expected to be used for general corporate purposes, including the funding of the Company's wind turbine installation vessel newbuilding program consisting of one contracted newbuilding vessel, one optional newbuilding vessel and one proposed Jones Act compliant newbuilding vessel. As part of the Offering, Scorpio Holdings Limited, a related party of the Company, has expressed an interest to purchase Common Shares at the public offering price with a value of at least $30.0 million.

07:42 EST NFI's ARBOC named in two-year cooperative contract with California's MBTA - ARBOC Specialty Vehicles, a subsidiary of NFI Group, announced a two-year contract with Morongo Basin Transit Authority, MBTA, executed on its behalf by ARBOC distributor Creative Bus Sales. The contract, which includes up to three one-year extensions, will be available to participating members of the California Association for Coordinated Transportation, CALACT, to make purchases of ARBOC vehicles. "Today's announcement is another example of cooperatives working together to efficiently deploy mobility at scale," said Paul Soubry, President and Chief Executive Officer, NFI. "NFI is pleased to support this cooperative contract facilitating procurement across the state of California, but more importantly, to continue expanding ARBOC's leading low-floor solutions into communities across California who depend on fully accessible transit and shuttle services." The contract, which includes ARBOC's Mobility, Independence, Freedom, and for the first time, the Equess, was placed through ARBOC distributor Creative Bus Sales and provides CALACT members direct access to purchase a variety of transit vehicles.

07:40 EST Rekor Systems comments on the American Jobs Plan legislation - Rekor Systems commented on the emphasis on transportation infrastructure in the American Jobs Plan legislation released this week. "The need to modernize the nation's transportation infrastructure has been long evident and the time is right now to rebuild quickly, intelligently, efficiently and cost effectively. Smart infrastructure can be an incredibly powerful agent in making our communities safer, cleaner and more equitable places to live and work," said Robert Berman, CEO of Rekor Systems. "As we've seen proven in numerous recent installations and pilot projects, intelligent infrastructure can be readily deployed, helping federal, state and local departments and agencies across the country rapidly address a full spectrum of priorities from public safety and transportation to emissions reductions and insurance compliance." Berman continued, "We know these real-time solutions drive improved traffic flow, safety, sustainability and economic development. The enactment of this infrastructure bill provides an unprecedented opportunity for us to rapidly accelerate the development of safer and more efficient communities throughout the country. This legislation takes a major step forward toward ensuring that these public benefits are delivered to all Americans." Rekor's safety and efficiency impact by the numbers: 18% reduction in primary crashes on monitored roads; 21% increase in incidents identified; 9.71% decrease in emissions within the area affected by an incident; 9-minute reduction in incident identification time; and 41,547 previously uninsured vehicles registered with OK UVED program since January 2021.

07:38 EST The Real Brokerage appoints Katharine Mobley as Chief Marketing Officer - The Real Brokerage (REAX) announced that Katharine Mobley will join its management team as Chief Marketing Officer. Mobley will be responsible for driving brand awareness. As a proven global brand builder and thought leader Mobley aims to expand Real's national and international footprint. Additionally, as Chief Marketing Officer, Mobley will be instrumental in other corporate initiatives such as Real's Environmental, Social, Governance, or ESG, program and corporate events. Mobley is an award-winning executive with more than 20 years of experience. Mobley focuses on delivering strategic and data-driven strategies for growth, venture-backed and private equity companies. Previously, Mobley led global marketing at First Advantage (FA). Prior to her role at First Advantage, Mobley served as a chief marketing officer at several technology firms and managed a range of global brands with accounts at several Fortune 500 companies.

07:37 EST ZW Data Action authorized as business expansion service provider for JD.com - ZW Data Action Technologies (CNET) announced that its wholly-owned subsidiary ChinaNet Online Technology was authorized by JD.com (JD) as a business expansion service provider for JD's WanDianBao business. WanDianBao is a micro service for JD online stores. It can assist enterprises to quickly and conveniently start the e-commerce marketing model and occupy the market. ZW Data was authorized as WanDianBao's business development services provider, including business expansion and customer services. The company can add blockchain resume services to JD's microservices to help microshops use the blockchain to increase the authenticity and trust for their products. ZW Data assists WanDianBao in establishing relationships with tens of thousands of merchants through inbound and outbound traffic. In addition, combined with the capabilities of WanDianBao, ZW Data's merchants could quickly build exclusive private domain online shopping malls, expand store sales categories, implement asset-light and burden-free sales business model, and carry out private domain refined operation cooperation through JD's supply chain connectivity, which forms a strategic synergy with ZW Data's new retail business. "ZW Data is committed to the implementation of the full spectrum of marketing promotion services supported by big data, such as big data marketing, traffic advertising, private domain operations, content marketing, and others for customers to explore new methods of the Uni Marketing. ZW Data will invest more advantageous resources and have more long-term and in-depth cooperation with JD in the future in the area of Uni Marketing," commented Handong Cheng, Chairman and Chief Executive Officer of ZW Data.

07:35 EST EyeGate announces name change to Kiora Pharmaceuticals - Kiora Pharmaceuticals (KPRX) is the new name of EyeGate Pharmaceuticals (EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company's aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. Kiora's pipeline now consists of three assets in early to late-stage development for both common and rare eye diseases. The company anticipates achieving several milestones for these programs that will drive value in the organization. KIO-101, previously known as PP-001, is a next-generation small molecule inhibitor of Dihydroorotate Dehydrogenase. It has demonstrated picomolar potency with a validated mechanism that may offer greater safety and tolerability than DHODH inhibitors currently on the market. Anticipated milestones include: Report topline data in fourth quarter of 2021 on a Ph1/2a safety, PK and exploratory ocular surface inflammation trial. Explore licensing opportunities for non-core indications. KIO-301, previously known as B-203, is a light-sensitive small molecule that acts as a reversible 'photoswitch', specifically designed to restore the eyes' ability to perceive and interpret light in visually impaired patients. KIO-301 selectively enters specific retinal ganglion cells and converts them into light sensing cells, capable of signaling the brain as to the presence or absence of light. Anticipated milestones include: Initiate a Phase 1b clinical trial in the third quarter of 2022 in patients with later-stage Retinitis Pigmentosa. Apply for orphan drug designation in the U.S. in the first quarter of 2022. Further develop the platform for use in patients with Geographic Atrophy, the later stages of Age-Related Macular Degeneration. KIO-201, previously known as Ocular Bandage Gel or "OBG", is a modified form of the natural polymer hyaluronic acid designed to accelerate ocular surface wound healing. Kiora will be discussing the Phase 3b readiness of KIO-201 for patients undergoing photorefractive keratectomy surgery for corneal wound repair with the FDA, whilst performing an additional exploratory phase 2 clinical trial in patients with persistent corneal epithelial defects. Anticipated milestones include: Pre-IND meeting with the FDA in the first quarter of 2022 to confirm Phase 3b readiness in PRK surgery. Report topline proof of concept, exploratory phase 2 clinical trial data in persistent epithelial defect patients in the third quarter of 2022.

07:34 EST FTI Consulting commits to net-zero greenhouse gas emissions by 2030 - FTI Consulting announced its commitment to achieve net-zero greenhouse gas, GHG, emissions by 2030. The Company will identify emission reduction targets for Scope 1 and Scope 2 emissions, as well as business travel, in 2022 and intends to work toward having these goals validated by the Science Based Targets initiative, SBTi. The commitment was made as part of FTI Consulting's inaugural Corporate Sustainability Report, which explains the Company's approach to its environmental, social and governance risks and opportunities, programs, policies, practices and goals. FTI Consulting will move toward reaching its net-zero GHG emissions goal in part through its environmental sustainability efforts.

07:31 EST Mindset Pharma announces presentation of preclincal data for MSP-1014 - Mindset Pharma announced a poster presentation of preclinical benchmarking data for the Company's optimized psilocybin analog, MSP-1014, compared to first generation psychedelic compounds at Society for Neuroscience 50th Annual Meeting: Neuroscience 2021 to be held virtually on November 8-11, 2021. The poster titled, "Characterisation of Behavioural, Safety and Pharmacokinetics Properties of Psilocybin and Psilocin in Rodents," will be presented by Dr. Guy Higgins, member of Mindset's Scientific Advisory Board and Chief Scientific Officer of InterVivo Solutions, on Monday, November 8th at 1:00 p.m. ET. The presentation includes data on the pharmacokinetic/pharmacodynamic relationship between behaviors associated with the 5-HT2A receptor engagement induced by psilocybin and psilocin. Mindset's previously announced efficacy and safety data on its psilocybin analog, MSP-1014, will be featured in the presentation.

07:29 EST 5.11 announces filing of registration statement for proposed IPO - 5.11 ABR Corp., a Compass Diversified subsidiary, announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. 5.11 intends to list on the Nasdaq Global Market under the ticker symbol "VXI." Morgan Stanley, Jefferies and Baird will act as lead book-running managers for the proposed offering. William Blair and Raymond James will act as book-running managers for the proposed offering. Roth Capital Partners, CJS Securities, CIBC Capital Markets, Telsey Advisory Group, Loop Capital Markets and Academy Securities will act as co-managers for the proposed offering. The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to this offering, when available, may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, New York 10014, Attn: Prospectus Department; Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, New York 10022, Attn: Equity Syndicate Prospectus Department; or Robert W. Baird & Co. Incorporated., 777 East Wisconsin Avenue, Milwaukee, Wisconsin 53202, Attn: Prospectus Department.

07:28 EST OraSure appoints Nancy Gagliano, Anne Whitaker to board of directors - OraSure Technologies announced the appointment Nancy Gagliano, M.D. and Anne Whitaker to the Company's Board of Directors, effective November 8, 2021. Dr. Gagliano will serve as a Class III Director with an initial term expiring at the Company's 2024 Annual Meeting of Stockholders. Mrs. Whitaker will serve as a Class II Director with an initial term expiring at the Company's 2023 Annual Meeting of Stockholders. She will also serve on the Audit Committee of the Board. Dr. Gagliano most recently served as an executive leader of the National Institute of Health's RADx Tech, Rapid Acceleration of Diagnostics program. Mrs. Whitaker currently serves as Managing Partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, and is the current Chairperson of the Board of Aerami Therapeutics, a private life science company.

07:24 EST Marrone Bio receives Nasdaq notice of noncompliance with listing rule - Marrone Bio Innovations announced that it has received a letter from the Listing Qualifications Department of the Nasdaq Capital Market notifying the company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) as a result of the company's closing bid price being below $1.00 per share for 30 consecutive days. Under Nasdaq Listing Rules, the company has 180 calendar days from the date of the notification to regain compliance with Nasdaq Listing Rules. Thus, the company has until May 4, 2022, to regain compliance. To regain compliance, the closing bid price of the company's common stock on the Nasdaq Capital Market must be at least $1.00 per share for a minimum of 10 consecutive business days prior to the expiration of the compliance period on May 4, 2022. This notification has no immediate effect on the listing of the company's common stock on the Nasdaq Capital Market and the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "MBII" during this period. If the company does not regain compliance by May 4, 2022, the company may be eligible for a second 180 day compliance period, provided that, on such date, the company meets the continued listing requirement for market value of publicly held shares and all other applicable initial listing requirements for the Nasdaq Capital Market and the company provides written notice to Nasdaq of its intention to and plans for curing the deficiency during the second compliance period. The company will monitor the closing bid price for its common stock between now and May 4, 2022, and intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and to maintain the listing of its common stock on the Nasdaq Capital Market.

07:24 EST Curaleaf to acquire Tryke Companies for $286M - Curaleaf entered into a definitive agreement to acquire Tryke Companies, a privately held vertically integrated, multi-state cannabis operator, in a cash and stock transaction valued at approximately $286M. The transaction is expected to close in the second half of 2022, subject to customary approvals and conditions. Under the terms of the agreement, Curaleaf will pay $40M in cash at closing, with a remaining $75M in cash to be paid in equal installments on the first, second and third anniversaries of the closing. The stock portion of the transaction, which consists of 17M subordinate voting shares of Curaleaf, will also be paid in three equal installments on the first, second and third anniversaries of the closing. An incremental earnout of up to 1M Curaleaf Shares may be paid in 2023 based on the business exceeding certain EBITDA targets for the year 2022. Tryke has a strong financial profile, with a history of delivering significant revenue growth and compelling EBITDA margins in excess of 35%. Tryke is expected to record nearly $110M in full year 2021 revenue. Curaleaf expects the acquisition will be immediately accretive to the company's EBITDA margins and free cash flow generation. The closing of the transaction is expected to occur in the second half of 2022 subject to customary closing conditions, including the receipt of approval from the applicable state regulators, including the Nevada Cannabis Compliance Board.

07:22 EST Agrify announces 10-year partnership with Kief USA - Agrify announced it has signed a definitive agreement with its third Massachusetts-based Agrify Total Turn-Key Solution customer, Kief USA. Kief USA will be a tier 11 cultivator and manufacturer based in Attleboro, Massachusetts, and will be a fully integrated operator in the cannabis space with additional retail operations, following the receipt of all necessary licenses. Under the terms of the Agreement, Agrify has entered into a 10-year deal with Kief USA that includes the installation of 485 Vertical Farming Units at Kief USA's 84,000-square-foot facility, as well as architectural and engineering services, construction, recurring SaaS revenue, operations consulting, and brand licensing. Kief USA will be providing 20% of the total $24M construction cost, with Agrify, or Agrify's designated financing partner, to provide senior financing of the remaining 80% of the construction cost at 16.5% APR, which will be repaid within 24 months following the commencement of the first commercial production at the facility. Kief USA has also committed to contribute 20% of all VFU hardware costs. The partnership is expected to generate over $68.7M in revenue for Agrify over the first three years of the deal once cultivation starts.

07:20 EST Galmed announces results from ARMOR Phase 3 study - Galmed Pharmaceuticals announced results from histology and biomarkers analyses in the ongoing Open-Label Part of the ARMOR Phase 3 study. Galmed previously announced a substantial effect on fibrosis improvement based on histology, in the 16 first patients from the ongoing Open-Label Part of the ARMOR study. New analyses of biomarkers corroborate this effect showing statistically significant reductions in biomarkers associated with liver fibrosis including ALT, AST, Fib-4 and ProC-3. Reductions of a similar magnitude are seen in a cohort of the first 20 patients for which paired biopsy have been analyzed and a cohort of 50 patients for which biomarker data was analyzed based on all available data. Aramchol continues to show excellent safety and tolerability profile. Data support that higher dose of Aramchol could provide statistically and clinically meaningful effect on fibrosis in the upcoming double-blind placebo controlled part for submission of the ARMOR study to support an NDA under Sub-part H.

07:19 EST GURU Organic Energy announces launch of GURU Guayusa Tropical Punch - GURU Organic Energy announced the addition of GURU Guayusa Tropical Punch to its growing, plant-based energy drink family. Inspired by the Jivaro people of Ecuador and concocted in Quebec, Canada, GURU Guayusa Tropical Punch is infused with natural and organic energy-boosting ingredients. GURU Guayusa Tropical Punch is now available in most convenience and grocery stores across Quebec, through GURU's exclusive Canadian distribution partner, PepsiCo Beverages Canada, and will be available in other Canadian provinces in the spring of 2022.

07:18 EST Constellium announces the restart of Ravenswood Facility - Constellium announced the restart of its upgraded 144-inch cold rolling mill at its facility in Ravenswood, West Virginia. Ravenswood was awarded funding of nearly $9.5M in 2019 by the U.S. Department of Defense, DoD, under the Industrial Base Analysis and Sustainment, IBAS, Program to increase throughput, quality, and performance of cold rolled aluminum. The restart marks completion of the first phase of the project involving a complete teardown of the 1950s era mill to upgrade its mechanical, electrical, hydraulic, and process control systems. The team will now focus on the development of prototype manufacturing processes and cold rolled mill products that will be enabled by the advanced capabilities of the upgraded mill. Cold rolling, which compresses and elongates the plate, improves plate flatness and surface characteristics, and adds additional strength to the finished plate. "This achievement was made possible by our partnership with the IBAS program and the Department of Defense. It will enable us to produce higher performance and higher quality plate in the volumes needed by the DoD over the next decade," commented Buddy Stemple, CEO of Constellium Rolled Products Ravenswood. Secretary Salazar agreed, "the restart of the Ravenswood mill adds a new dimension to the supply chain for America's defense industry, and I am proud of the Ravenswood team for their commitment to our national and economic security."

07:17 EST Emerita Resources provides update on reports on Aznalcollar court proceedings - Emerita Resources is providing an update in response to current media reports in Spain concerning ongoing developments in the Aznalcollar legal case. The current flurry of news items is in response to a resolution issued by the Provincial Court No. 3 of Seville pursuant to which the Court has determined that it is appropriate to commence with the oral trial of the accused and that this trial should be conducted in the upper courts. Emerita's external Spanish legal counsel has advised that this resolution is part of the formal paperwork required for the trial process, which was expected but is encouraging, as it indicates the case is progressing. The Court is not waiting on the outcome of any appeals to the upper court by the accused which indicates a confidence that these will be denied based on the rulings to date. The Court has summoned the accused individually and notified them in person that they should prepare their final submissions without delay. Most significantly in counsel's view is that the Court did not have a lot more to say about the substance of the case and has ruled to advance the case to the upper court without delay." The next step in the criminal trial is that the upper court will receive the defense briefs and all trial documentation, which will be submitted to a nominated judge to set the date and complete the trial and issue the verdicts and penalties. The Administrative Court of Andalucia has also notified the Company that it will be making a ruling in the administrative case initiated by Emerita in 2015. This administrative process is separate from the ongoing criminal proceedings regarding the alleged crimes committed in the awarding of the Anzalcollar tender and this gives Emerita another path forward to obtaining the rights to the Aznalcollar project. The Company perceives the Administrative Court's notice as a very positive development as Emerita's external Spanish legal counsel has advised the Company that the Administrative Court has the authority to make a determination to award the Aznalcollar project to Emerita. The Company will provide further details of the Upper Court's and the Administrative Court's rulings as they unfold.

07:15 EST Helius Medical launches TEP with NYU Langone Health - Helius Medical Technologies announced the launch of its Therapeutic Experience Program, TEP, with NYU Langone Health as its first Center of Excellence. The TEP study is designed to assess adherence to Portable Neuromodulation Stimulaton, PoNS, therapy in patients with multiple sclerosis, MS. "We are excited to partner with one of the nation's premier academic medical centers on this important program aiming to provide US clinicians with the opportunity to evaluate PoNS therapy for MS patients with gait deficit in a real-world environment," said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. "Through NYU Langone Health and future Centers of Excellence, the TEP study will enable key opinion leaders in the management of MS to build their knowledge of PoNS therapy and advise the broader medical community."

07:13 EST 51job announces update on going-private transaction - 51job announced that certain members of the buyer consortium that formed Garnet Faith Limited to acquire the company pursuant to the previously announced agreement and plan of merger dated as of June 21, have been in consultation with Chinese regulators on recent regulatory changes in China that may be applicable to the company and the Proposed Transaction. The consultation process by these buyer consortium members is currently ongoing and a clear timeline to its completion cannot be provided at this time. The company intends to file an updated Schedule 13E-3 Transaction Statement as soon as possible, subject to the progress of the consultation process.

07:12 EST GreenPower Motor and Perrone Robotics announce OEM agreement - GreenPower Motor Company together with Perrone Robotics, a provider of fully autonomous vehicle, or AV, technology and turnkey vehicle solutions for the mobility of people and things, announced their Original Equipment Manufacturer, or OEM, agreement. Under this new agreement, the two companies will continue to build on the success of the original AV Star developed for the Jacksonville Transportation Authority, or JTA, in 2019. The original AV Star was developed to meet a growing demand in the transit and transportation sector where reliable mobility was a requirement to expand accessibility options for all end-users. Once deployed in 2019, the JTA AV Star became the nation's first fully autonomous, all electric, ADA-compliant, and FMVSS certified vehicle. The base EV Star vehicle is also Altoona tested and Buy America compliant.

07:11 EST Alnylam initiates KARDIA-2 trial - Alnylam announced initiation of KARDIA-2, a global Phase 2 study to evaluate the efficacy and safety of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen, or AGT, in development for the treatment of hypertension. KARDIA-2 will evaluate the efficacy and safety of zilebesiran administered biannually as a concomitant therapy in patients whose blood pressure is not adequately controlled by standard of care antihypertensive medications.

07:11 EST Axsome Therapeutics expects cash to fund operations into at least 2024 - Axsome believes that its cash at September 30, 2021, along with the remaining committed capital from the $300 million term loan facility, is sufficient to fund anticipated operations, based on the current operating plan, which includes costs for the potential commercial launch of AXS-05 in MDD and AXS-07 in migraine, into at least 2024. Axsome expects that its operating expenses will increase year over year as it continues to build out the commercial function and further advance its pipeline.

07:09 EST Origin Materials, Kolon Industries announce polymers partnership - Origin Materials and Kolon Industries announced a strategic partnership to industrialize novel polymers and drop-in solutions for select applications, with an initial focus on automotive applications. This strategic partnership aims to rapidly develop and industrialize new sustainable carbon-negative products based on Origin Materials' patented technology platform, leveraging Kolon's polymerization expertise, application development and supply chain strength. As part of the partnership, Kolon signed a multi-year capacity reservation agreement to purchase sustainable carbon-negative materials from Origin Materials. The partnership includes co-development aimed at commercializing polyethylene furanoate, or PEF, a polymer with an attractive combination of performance characteristics for packaging and other applications, including enhanced barrier properties when compared with polyethylene terephthalate, or PET, degradability, and other qualities. Origin Materials' technology platform is expected to produce cost-competitive, sustainable, carbon-negative furandicarboxylic acid, or FDCA, the primary precursor to PEF.

07:07 EST Regeneron says single dose of REGEN-COV cut risk of COVID-19 by 81.6% in study

07:05 EST AC Immune announces achieved, anticipated milestones - Clinical Milestones: ACI-35.030 anti-pTau vaccine: reported Phase 1b/2a interim results in AD patients in Q1; further Phase 1b/2a interim analysis in Q4; JACI-35.054 alternative anti-pTau vaccine: reported a Phase 1b/2a interim analysis in AD patients in Q2; Alpha-synuclein PET imaging agent: advanced third-generation candidate to first-in-human clinical study in Q1; data to be presented at upcoming scientific meeting. ACI-24 anti-Abeta vaccine in DS: reported Phase 1b topline results in Q1. ACI-24 in AD: reported Phase 2, 12-month interim analysis in Q1; reporting full data set at CTAD in November 2021; Semorinemab anti-Tau antibody partnered with Genentech: topline results reported in Q3 Small molecule Morphomer Tau aggregation inhibitor program: select NeuroOrphan indication for further development in H2; ACI-24 in DS: submit investigational new drug application for optimized vaccine formulation in Q4. Preclinical Milestones: Alpha-synuclein small molecule inhibitor: identified first biologically active small molecule in Q1; start in vivo proof-of-concept studies in Q4; Morphomer NLRP3-ASC: report in vivo proof-of-concept results in a non-central nervous system disease model and begin in vivo proof-of-concept studies with validated candidate in central nervous system in Q4; Anti- NLRP3-ASC antibody: begin in vivo proof-of-concept studies in Q4; Anti-TDP-43 antibody: initiate IND-enabling toxicology studies in Q4; TDP-43 biofluid diagnostic: establish validation-ready assay in Q4

07:04 EST AC Immune announces cognitive results for Tau-targeting monoclonal antibody - Announced the first cognitive results for a Tau-targeting monoclonal antibody in Alzheimer's disease. Topline data from the Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD showed a statistically significant43.6% reduction at week 49 in cognitive decline vs. placebo as measured by ADAS-Cog11, one of the trial's co-primary endpoints. The second co-primary endpoint, ADCS-ADL, was not met. AC Immune's partner Genentech is continuing with the trial's open label extension and is scheduled to present the topline data from the Lauriet study at the CTAD conference on November 10, 2021, at 10:50am EST.

07:01 EST ViaSat, Inmarsat to combine in $7.3B deal

06:49 EST International Game appoints Gil Rotem as president of iGaming - International Game announced that it has appointed Gil Rotem as president of iGaming, effective immediately. Reporting to Enrico Drago, IGT CEO Digital & Betting, Rotem is responsible for ensuring the ongoing development and global expansion of the IGT PlayCasino business, which includes iGaming, poker and bingo.

06:48 EST Lottery.com begins development of blockchain gaming platform - Lottery.com announced that it is in the early stages of development for a platform to operate lottery, sports betting, sweepstakes, and other forms of online gaming, as well as enhance the company's API capabilities. This multi-year project, called Project Nexus, is a component of the company's strategy to leverage blockchain-based technology to enhance the availability and security of the company's product offering. The company is currently in discussions with leading blockchain providers to partner on the development of Project Nexus. The blockchain-based elements of Project Nexus are expected to allow the company to provide improved transparency into results and enhanced security of every game it offers across gaming verticals. Once fully developed, the company plans to leverage Project Nexus to introduce multiple proprietary lottery games for players outside the U.S., with the potential for multi-billion dollar shared jackpots. The platform is expected to provide users with the ability to vote on the allocation of a portion of the proceeds from these jackpots toward social and environmental causes. Additionally, Project Nexus is intended to allow players in permitted jurisdictions to utilize fiat or crypto payments to play these proprietary games, thereby opening these games to a larger market.

06:47 EST US Foods CEO expects supply chain headwinds into 2022 - "In the third quarter, US Foods' continued operational and financial discipline helped drive increased volumes and profitable growth," said Chairman and CEO Pietro Satriano. "While supply chain headwinds persist and are expected to continue into 2022, we're pleased to see tangible and enduring signs that the industry is recovering, which allows us to refocus our energy and resources on our Great Food. Made Easy. strategy. We are focused on profitably growing market share, smartly optimizing our margins and improving operational efficiencies. Together, these initiatives are designed to position US Foods to benefit from a strengthening economy and create value for our shareholders."

06:40 EST KalVista announces data at ACAAI from Phase 2 data for KVD900 - KalVista Pharmaceuticals announced data presented at American College of Allergy, Asthma & Immunology, or ACAAI, Annual Scientific Meeting. Data presentations included an oral presentation and poster presentation on Phase 2 data for KVD900, KalVista's lead program for oral on-demand treatment of hereditary angioedema, or HAE, attacks. "Current guidelines recommend effective on-demand therapy for every patient with HAE to reduce symptom severity and attack duration," said Jonathan Bernstein, FAAAAI, FACAAI, FACP,University of Cincinnati College of Medicine and Bernstein Clinical Research Center. "Treatment of HAE attacks with KVD900 achieved rapid plasma exposure which was associated with faster improvements in initial symptom relief compared with placebo. As the first oral on-demand treatment to demonstrate this early therapeutic effect for patients, KVD900 may represent a remarkable advancement for management of the disease."

06:33 EST Coty to sell 4.7% stake in Wella to KKR in transaction valued at $215.7M - Coty (COTY) announced a definitive agreement to sell an approximate 4.7% stake in Wella to KKR (KKR) in exchange for the redemption of approximately 56% of KKR's remaining convertible preferred shares in Coty. This transaction reduces Coty's total shareholding in the professional beauty company to approximately 25.9%. The structure and terms of the transaction are consistent with the previous transaction announced on October 1, 2021 in which Coty agreed to exchange a 9% stake in Wella for the equivalent of approximately 47M shares of the company's common stock. Both transactions reflect an approximately 50% appreciation in Wella's equity value since the closing of Coty's 60% sale of Wella to KKR in December 2020, coinciding with the re-opening of global hair salons and the positive momentum in the Wella business. As consideration for KKR's purchase of shares in Wella from Coty, Coty will redeem approximately 56% of KKR's outstanding convertible preferred shares and accrued dividends, or the equivalent of approximately 25M shares of the company's common stock, for approximately 4.7% of Wella held by Coty in a transaction valued at approximately $215.7M. Upon completion of the transaction, KKR will continue to have a 2.4% ownership stake in Coty on an as-converted basis. The latest transaction will further simplify Coty's capital structure and result in an additional approximately $14M in annual dividend cash savings, totaling approximately $65M in annual cash savings when combined with the two previous transactions with KKR in September and October. The deal will have additional accretive benefits to Coty through the reduction of its diluted share count. The transaction is expected to close in the coming weeks.

06:15 EST Wyndham to receive $84M in termination fees from CorePoint Lodging - Wyndham Hotels & Resorts (WH) announced that it has entered into a definitive agreement with CorePoint Lodging (CPLG) concerning the termination of all remaining Wyndham hotel management agreements, or HMAs, upon consummation of the merger announced by CPLG. The termination is conditioned upon the closing of CPLG's sale, which is targeted to occur in Q1 of 2022. Upon termination of the HMAs, CPLG will pay termination fees to Wyndham of approximately $84M. Wyndham's related franchise agreements are expected to remain in-place at the current fee structure.

06:12 EST FiscalNote to become public through Duddell Street Acquisition combination - FiscalNote and Duddell Street Acquisition (DSAC) announced that they have entered into a definitive business combination agreement that will result in FiscalNote becoming a publicly listed company with a pro forma market capitalization of approximately $1.3B. Upon closing, the combined company will operate under the FiscalNote name and trade on the Nasdaq under the ticker symbol (NOTE). FiscalNote has more than 3,000 subscription customers across a range of global enterprises, small and medium-sized businesses, non-profits, and the public sector. The transaction implies a pro forma market capitalization of approximately $1.3B for the combined company, representing a multiple of approximately 6.9x enterprise value to 2022E pro forma revenue. Current FiscalNote equity holders will roll 100% of their equity interests into the combined company and will retain approximately 76% ownership. Existing FiscalNote equity holders will be under a lock-up of at least six months from the closing of the transaction and have the potential to receive an earnout of additional shares of common stock of the combined company if certain stock price targets are met as set forth in the definitive business combination agreement. Concurrently with the consummation of the proposed business combination, investors have committed to purchase $100M of common stock of the combined company in a fully committed private placement at $10.00 per share. Upon closing, the transaction will provide approximately $275M of gross proceeds to the combined company, comprised of approximately $175M of cash held in the trust account of Duddell Street, with redemptions of the trust account backstopped by Maso Capital, and $100M in the fully committed PIPE, with participation from global institutional investors. Gross proceeds are expected to far exceed the minimum cash condition of $190M as set forth in the definitive business combination agreement. The proceeds from the transaction will further strengthen FiscalNote's ability to execute on significant near-term organic and inorganic growth opportunities globally as it continues to develop and deliver products to serve the regulated industries of the future. The boards of both FiscalNote and Duddell Street have each unanimously approved the proposed business combination, which is expected to be completed in Q1 of 2022, subject to, among other things, the approval of the business combination by Duddell Street's and FiscalNote's shareholders, the concurrent PIPE transaction, satisfaction of the conditions stated in the definitive business combination agreement and other customary closing conditions, including that the U.S. Securities and Exchange Commission completes its review of the registration statement on Form S-4 and the proxy statement/prospectus that Duddell Street will file with the SEC, the receipt of certain regulatory approvals, and approval by The Nasdaq Stock Market to list the securities of the combined company.

06:04 EST CorePoint Lodging to be acquired by affiliates of Highgate, Cerberus for $1.5B - CorePoint Lodging (CPLG) announced that it has entered into a definitive agreement to be acquired through a joint venture between affiliates of Highgate and Cerberus Capital Management. Under the terms of the merger agreement, Highgate and Cerberus will acquire all outstanding shares of CorePoint common stock in an all-cash transaction valued at approximately $1.5B based on the $15.65 per share consideration, which reflects the assumption of current net debt and a $160M buyer liability reserve for the Internal Revenue Service matter detailed below. This price represents a premium of approximately 42% to CorePoint's closing share price on July 13, 2021, the last trading day prior to the Company's public announcement of its strategic alternatives process. In addition to the $15.65 per share payable in cash at closing, CorePoint stockholders may receive incremental cash consideration per share pending timely resolution of the previously disclosed tax proceedings with the IRS related to an ongoing audit of CorePoint entities, which began prior to the company's 2018 spin-off from La Quinta Holdings, Inc. The amount of any potential additional cash consideration payable to CorePoint stockholders will be calculated based on the amount, if any, by which the settlement amount is less than a buyer liability reserve of $160M agreed to by the parties. The company received a settlement offer from the IRS with respect to the IRS matter on November 5, 2021, and expects to accept that offer and enter into an agreement with the IRS this week. The settlement offer provides for total payments by the company of approximately $89.6M plus statutory interest through the date of payment. Pursuant to this settlement offer, the company estimates the total payment amount pursuant to the settlement will be approximately $155M. As such, the company currently expects that the amount of any such additional consideration will likely be approximately 10c per share. There can be no assurances that any additional consideration will be received by the company's stockholders. The transaction is expected to close in the first quarter of 2022, subject to the approval of CorePoint's stockholders and the satisfaction of other customary closing conditions. There is no financing condition to the transaction. In connection with the transaction, affiliates of Blackstone (BX) which own approximately 30% of CorePoint's total shares outstanding, have entered into a voting agreement under which they have agreed to vote all of their shares in favor of the transaction. Upon successful completion of the transaction, CorePoint's common stock will no longer be listed.

05:49 EST Liquidia Technologies receives tentative approval from FDA for Yutrepia - Liquidia announced that the FDA granted tentative approval for Yutrepia inhalation powder, previously referred to as LIQ861. Yutrepia is indicated for the treatment of pulmonary arterial hypertension, or PAH, to improve exercise ability in adult patients with New York Heart Association, or NYHA, Functional Class II-III symptoms. Tentative approval indicates that Yutrepia has met all regulatory standards for quality, safety and efficacy required for approval in the United States.

05:46 EST Alcon to acquire Ivantis for $475M upfront - Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent, a minimally-invasive glaucoma surgery, or MIGS, device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery. The intended acquisition affirms Alcon's commitment to the surgical glaucoma space. The five-year HORIZON clinical study of Hydrus Microstent is the longest, continuous follow-up of a MIGS device. It demonstrated that 65% of Hydrus Microstent patients remained medication-free at five years post-implant. The results also showed over 60% reduction in risk of invasive secondary glaucoma surgeries compared to cataract surgery alone - and its safety profile was sustained through the five-year follow up. Among MIGS rated in the 2020 American Academy of Ophthalmology Primary Open-Angle Glaucoma Preferred Practice Pattern, or PPP, the Hydrus Microstent received the highest grade for quality body of evidence and a strong recommendation. Alcon will pay $475M in upfront consideration to acquire Ivantis, Inc. Alcon may be required to make additional contingent payments upon the achievement of certain regulatory and commercial milestones. The transaction is anticipated to close in Q1 of 2022 subject to customary closing conditions, including regulatory approval.

05:38 EST Blackstone to invest $250M in Autolus Therapeutics for obecabtagene autoleucel - Autolus Therapeutics (AUTL) and Blackstone Life Sciences announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone (BX) will provide up to $250M in equity and product financing to support Autolus' advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel, as well as next generation product therapies of obe-cel in B-cell malignancies.As part of this $250M transaction, Blackstone is committing to invest $150M in product financing to support obe-cel development and commercialization, with $50M payable upon closing of the transaction and the remainder payable based on certain development and regulatory achievements. Blackstone has also agreed to purchase $100M of Autolus' American depositary shares in a private placement, which is subject to customary closing conditions. In connection with the collaboration, Blackstone received the right to nominate a member to Autolus' board of directors.

05:28 EST Philips to acquire Cardiologs, terms undisclosed - Philips announced that it has signed an agreement to acquire Cardiologs, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence and cloud technology. The transaction, which is subject to customary closing conditions, is expected to be completed in the coming months. Financial details of the transaction were not disclosed. Cardiologs' technology is built on a growing database of more than 20M ECG recordings and supported by a number of clinical publications. Cardiologs was founded in 2014 and is headquartered in Paris, France. Its approximately 70 employees, largely comprising software engineers and data scientists with expertise in AI and deep learning algorithms, will join Philips and will expand the company's continued AI-focused innovation activities together with the company's R&D lab in Paris

05:23 EST ChipMOS reports October revenue $82.3M, up 10.7% - Revenue for the month of October was $82.3 million, an increase of 10.7% compared to October 2020 and a decrease of 2.3% compared to September. The company noted it is benefitting from a better product mix, with its DDIC high-end test and memory platforms remaining at a high utilization level.

05:08 EST Genetron, NeoGenomics partner to provide China focused trials - Genetron (GTH) announced that it has entered into a strategic partnership with NeoGenomics (NEO).Genetron Health and NeoGenomics will partner globally to provide select harmonized clinical trials, global translational research for pharmaceutical groups and technology platform providers that need a China arm for global or China focused trials. Additionally, NeoGenomics will support Genetron Health on ex-China trials requiring U.S., APJ and/or EMEA based trials. This will include developing and operating clinical trials for both oncology drugs and their corresponding companion diagnostics products.The partnership will leverage a technology platform and product pipeline that covers molecular detection, histopathologic diagnosis, multi-fluorescence immunohistochemistry, flow cytometry, immunoassays, in situ hybridization and cell genetic mapping. Combined, the two will have 15 CAP-accredited and CLIA-certified laboratories, a collective team of hundreds of scientists from multidisciplinary backgrounds, and a clinical drug trial and pharmaceutical services team. These assets will enable business partners to synchronize global clinical drug trials and companion diagnostics development.